Emerging adenosine receptor agonists
Key result
Selective adenosine receptor agonists are currently in clinical trials for various conditions including cardiac arrhythmias and rheumatoid arthritis, though none have yet received regulatory approval.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Selective adenosine receptor agonists are emerging as potential therapeutic agents across multiple cardiovascular and non-cardiovascular indications currently under clinical investigation.
Structured PICO
I
Intervention
Adenosine receptor agonists (A1, A2A, A2B, and A3 subtypes)
Selective adenosine receptor agonists are emerging as potential therapeutic agents across multiple cardiovascular and non-cardiovascular indications currently under clinical investigation.
Cite This Study
Gao et al. (2007) conducted a review in Various conditions (cardiac arrhythmias, neuropathic pain, rheumatoid arthritis, colorectal cancer). Adenosine receptor agonists was evaluated. Selective adenosine receptor agonists are currently in clinical trials for various conditions including cardiac arrhythmias and rheumatoid arthritis, though none have yet received regulatory approval.